Efficacy of Triptolide for Children with Moderately Severe Henoch-Schönlein Purpura Nephritis Presenting with Nephrotic Range Proteinuria: A Prospective and Controlled Study in China

Table 3

Long-term prognosis in different groups with moderately severe Henoch-Schönlein purpura nephritis.

Group	Cases	Follow-up times (months)	A	B	C	D
Treatment	42	40.76±19.18	29 (69%)	9 (21%)	2 (5%)	2 (5%)
Control	14	38.14±22.51	8 (57.1%)	2 (14.3%)	2 (14.3%)	2 (14.3%)

𝜒²=3.111, 𝑃=0.097. (A) Normal and minor urinary abnormalities (including healthy patients without urinary abnormalities and those with microalbuminuria (UA/C 2.5–25 mg/mmol) with or without hematuria); (B) persistent mild proteinuria and GFR ≥90 mL/min/1.73 m² (two standard deviations below the mean value of controls) with or without hematuria; (C) active renal disease (hypertension with mean arterial pressure (MAP) >95th percentile and/or UA/C ≥200 mg/mmol and/or GFR 60–90 mL/min/1.73 m²) with or without hematuria; (D) chronic renal failure (CRF) (GFR ≤60 mL/min/1.73 m²) or end-stage renal disease (ESRD, requiring dialysis and/or renal transplantation).